LFG316A2203
Posted by: Georgia Retina in
Research Title: A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration Sponsor: Novartis Principal Investigator: Mark J. Rivellese, M.D. Description: This study is designed to test the efficacy of six successive monthly doses of intravitreal (IVT) LFG316 on the growth of geographic atrophy (GA) lesions. The study will also…
Read More
OPH1004
Posted by: Georgia Retina in
Research Title: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration. Sponsor: Ophthotech Corporation Principal Investigator: Atul Sharma, M.D. Description: Subjects will be randomized…
Read More MARINA FVF2598g
Posted by: Georgia Retina in
Research Title: A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration Sponsor: Genentech Principal Investigator: Jay Stallman, M.D. Description: The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety…
Read More Novartis CSPP100A2244
Posted by: Georgia Retina in
Research Title: Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema Sponsor: Novartis Principal Investigator: Robert Stoltz, M.D Ph.D Description: To evaluate the efficacy of oral Aliskiren on diabetic macular edema, as measured by improvement in OCT macular thickness after 12 weeks of therapy. Start Date: August 2009 Recruitment: Completed Project Personnel: Leslie Marcus, CCRC Location(s): Marietta; 114 Cherry St., Suite F,…
Read More Ocriplasmin Research to Better Inform Treatment (ORBIT)
Posted by: Georgia Retina in
Research Title: This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited across approximately 120 USA retina sites. Sponsor: ThromboGenics Principal Investigator: Michael Jacobson, M.D. Description: The sites…
Read More OPH1002
Posted by: Georgia Retina in
Research Title: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration. Sponsor: Ophthotech Corporation Principal Investigator: Atul Sharma, M.D. Description: Subjects will be randomized in a 1:1 ratio to…
Read More Ophthotech OPH2003
Posted by: Georgia Retina in
Research Title: A Phase 2B Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Sponsor: Ophthotech Corporation Principal Investigator: Atul Sharma, M.D. Description: The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura®…
Read More PDEX
Posted by: Georgia Retina in
Research Title: Triple Therapy — PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration Sponsor: Bay Area Retina Associates Principal Investigator: Atul Sharma, M.D. Description: The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of…
Read More Regeneron R2176-3-AMD-1417 CAPELLA
Posted by: Georgia Retina in
Research Title: A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity…
Read More Regeneron R910-3-AMD-1517 ONYX
Posted by: Georgia Retina in
Research Title: A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Realted Macular Degeneration. Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI). Start…
Read More 
